D2G Oncology
Mountain View, US · Founded 2018 · Delaware corporation · 1 known investors
Find your way into D2G Oncology
Founders & leadership
JM
Jonathan MacQuittyNamed on SEC filing
KD
Kathleen D. LaPorteNamed on SEC filing
DP
Dmitri PetrovNamed on SEC filing
MW
Monte WinslowNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$8.7M disclosed across 1 round · 2020
▶$8.7MraisedApr 2020 · 12 investors · BiotechnologyRule 506(b)
▶$8.7MraisedApr 2020 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan MacQuittyExecutive Officer, Director
- Kathleen D. LaPorteDirector
- Dmitri PetrovDirector
- Monte WinslowDirector
- Offering amount
- $8.7M
- Amount sold
- $8.7M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- Who are D2G Oncology's investors?
- D2G Oncology's investors include Lightspeed Venture Partners.
- How much funding has D2G Oncology raised?
- D2G Oncology has disclosed $8.7M raised across 1 round.
- Where is D2G Oncology headquartered?
- D2G Oncology is headquartered in Mountain View, US.